Comparison of complication risk for open carpal tunnel release: In-office versus operating room settings

BACKGROUND: Performing open carpal tunnel release (oCTR) in an office-based procedure room setting (PR) decreases surgical costs when compared with the operating room (OR). However, it is unclear if the risk of major medical, wound, and iatrogenic complications differ between settings. Our purpose was to compare the risk of major medical complications associated with oCTR between PR and OR settings. METHODS: Utilizing the MarketScan Database, we identified adults undergoing isolated oCTR between 2006 and 2015 performed in PR and OR settings. ICD-9-CM and/or CPT codes were used to identify major medical complications, surgical site complications, and iatrogenic complications within 90 days of oCTR. Multivariable logistic regression was used to compare complication risk between groups. RESULTS: Of the 2134 PR and 76,216 OR cases, the risk of major medical complications was 0.89% (19/2134) and 1.20% (914/76,216), respectively, with no difference observed in the multivariable analysis (adjusted odds ratio [OR] 0.84; 95% CI 0.53–1.33; P=0.45). Risk of surgical site complications was 0.56% (12/2134) and 0.81% (616/76,216) for the PR and OR, respectively, with no difference in the multivariable analysis (OR 0.68; 95% C.I. 0.38–1.22; P=0.19). Iatrogenic complications were rarely observed (PR 1/2134 [0.05%], OR 71/76,216 [0.09%]), which precluded multivariable modeling. CONCLUSION: These results support a similar safety profile for both the PR and OR surgical settings following oCTR with similar pooled major medical complications, pooled wound/surgical site complications, and iatrogenic complications

Effect of intravenous glucagon on the survival of rats after acute occlusive mesenteric ischemia

The purpose of this study was to determine the optimal timing of intravenous glucagon infusion for the treatment of acute occlusive mesenteric ischemia. The superior mesenteric artery (SMA) was occluded for 85 min in 106 Sprague--Dawley anesthetized rats. The animals were divided into 12 treatment groups according to the timing of glucagon and saline administration, and survival was measured to 48 hr. Without treatment, all rats died within 24 hr. Intravenous saline (10 ml/kg/hr) for 2 hr did not significantly improve 48-hr survival (17-33%). Glucagon (1.6 [mu]g/kg/min iv) plus saline (10 ml/kg/hr iv) for 2 hr after SMA occlusion significantly improved survival from 33% (saline control) to 83% (P P < 0.02). Adequate saline infusion was required for glucagon efficacy after ischemia, as shown by an intermediate 48-hr survival of 50% when only maintenance saline (1.5 ml/kg/hr) was given. These data suggest that glucagon therapy should be delayed until after operative release of an acute SMA occlusion and should be accompanied by vigorous volume expansion.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/25685/1/0000239.pd

Major Lower Extremity Amputation in Veterans Affairs Medical Centers

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/42433/1/10016-14-3-216_00140216.pd

Outcomes after Abdominal Aortic Aneurysm Repair in Those ≥80 Years of Age: Recent Veterans Affairs Experience

= 231) of the patients. A total of 5833 patients underwent repair of nonruptured AAA: mortality was 4.1% (228/5627) in those <80 and 8.25% (17/206) in those ≥80 years old ( p < 0.009). Logistic regression analysis indicated age ≥80 was independently associated with higher mortality (odds ratio 1.834:1, 95% bounds 1.117-3.012). Octogenarian status (defined as ≥80 years of age), however, had a less important association with in-hospital death than did surgical complications of the heart or genitourinary tract, postoperative hemorrhage, septicemia, respiratory insufficiency, myocardial infarction (MI), acute renal failure, surgical complications of the central nervous system (CNS), aneurysm rupture, postoperative shock, or disseminated intravascular coagulation (DIC), in ascending order of importance. Only 5.9% ( n = 25) of the 427 patients undergoing repair of ruptured AAA were ≥80 years old. In those ≥80 undergoing repair of ruptured aneurysms, mortality was 48% which did not differ from the 45% mortality in those <80 (NS). The likelihood that one would be operated for rupture was statistically greater (1.66:1) for those ≥80 years ( p < 0.025). Length of stay (LOS) for those ≥80 undergoing AAA repair was longer being 22.3 ± 14.8 days versus 18.3 ± 13.2 days for younger patients ( p < 0.001). Mortality and LOS after AAA repair were statistically greater for those ≥80 years of age. Severity of illness, however, was also greater for octogenarians. Patient Management Category (PMC) software defined illness severity was 4.06 ± 1.22 in octogenarians versus 3.84 ± 1.13 for those younger ( p < 0.005). Though age ≥80 was independently associated with increased mortality, selected elderly patients could benefit from AAA repair.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/42431/1/10016-12-2-106_12n2p106.pd

Hypoxanthine-guanine phosphoribosyltransferase-independent toxicity of azathioprine in human lymphoblasts

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/24724/1/0000146.pd

Greater Trochanteric Pain Syndrome

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/135686/1/jum201635112413.pd

Comparative hemodynamic effects of selective superior mesenteric arterial and peripheral intravenous glucagon infusions

This experiment was designed to determine whether any hemodynamic benefits attend administration of equal pharmacologic doses of glucagon (1 [mu]g/kg/m) by continuous intravenous infusion (Group I, n = 6) versus selective intraarterial infusion (Group II, n = 6) via the superior mesenteric artery (SMA) in dogs. Cardiac output, heart rate, mean arterial pressure, total peripheral resistance, pulmonary vascular resistance, superior mesenteric artery flow (SMAQ), SMA vascular resistance, and portal venous pressure were measured at baseline (BL) and at 5, 15, 30, and 45 min during glucagon infusion. SMAQ virtually doubled at 5 min from a baseline of 570 +/- 60 ml/min to 1158 +/- 146 ml/min in Group I (P P P P &lt; 0.05). Changes in systemic hemodynamic parameters, as well as glucagon and glucose levels were not statistically different between Groups I and II at any time period. Glucagon is a potent mesenteric vasodilator and the resultant profound splanchnic hemodynamic effects are as marked during intravenous administration as during selective SMA infusion.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/25582/1/0000126.pd

Dissociation of glucagon's central and peripheral hemodynamic effects: Mechanisms of reduction and redistribution of canine hindlimb blood flow

Effects of parenterally administered pharmacologic doses of glucagon on canine hindlimb blood flow were studied. Cardiac output (CO), mean arterial pressure (MAP), total peripheral resistance (TPR), common femoral artery flow (CFAQ), common femoral artery resistance (CFAR), percentage shunt in the hindlimb (AVA%) determined by 99mTc microsphere technique, the volume of hindlimb shunt flow (AVAQ), and the volume of hindlimb nutrient capillary flow (NCQ) were determined at baseline and at 10, 20, and 30 min during continuous intravenous infusion of 1 [mu]g/kg/min glucagon (n = 8). Blood glucagon and glucose levels were measured at all time periods. Glucagon infusion significantly increased CO throughout the infusion, while reducing MAP and TPR. Unexpectedly, CFAQ decreased significantly despite the increase in CO. CFAR increased despite the reduction of TPR during glucagon infusion. The reduction of CFAQ was associated with diminished nonshunt hindlimb NCQ and increased AVA%. Changes in CFAQ, AVA%, AVAQ, and NCQ did not correlate in a linear fashion with the changes in either blood glucose or glucagon levels by linear regression analysis. Glucagon appeared to cause a major redistribution of peripheral blood flow. Hindlimb arteriolar dilatation was not an effect of this hormone in this experimental model. Glucagon appeared to have a salutary central hemodynamic effect, but was detrimental to canine extremity perfusion.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/24416/1/0000686.pd

A rare cause of chronic mesenteric ischemia from fibromuscular dysplasia: a case report

<p>Abstract</p> <p>Introduction</p> <p>Chronic mesenteric ischemia is a condition that is classically associated with significant atherosclerosis of the abdominal arteries, causing postprandial abdominal pain out of proportion to physical examination. The abdominal pain is exacerbated after meals due to the shunting of blood away from the intestines to the stomach, causing relative ischemia. More than 95% of chronic mesenteric ischemia cases are due to atherosclerosis. We report the first known case of chronic mesenteric ischemia from fibromuscular dysplasia. To the best of our knowledge, this is also the first known case in the literature where postprandial abdominal pain was the presenting symptom of fibromuscular dysplasia.</p> <p>Case presentation</p> <p>A 44-year-old Caucasian woman with a history of hypertension and preeclampsia, who had taken oral contraceptive pills for 15 years, presented with an intractable, colicky abdominal pain of two weeks duration. This abdominal pain worsened with oral intake. It was also associated with diarrhea and vomiting. Physical examination revealed stage III hypertension out of proportion to her risk factors and diffuse abdominal pain without peritoneal signs. An abdominal computed tomography scan, completed in the emergency room, revealed nonspecific colitis. Laboratory work revealed leukocytosis with a left shift, an erythrocyte sedimentation rate of 79 and a C-reactive protein level of 100. She was started on intravenous flagyl and intravenous ciprofloxacin. However, all microbial cultures were negative including three cultures for clostridium difficile. Urine analysis revealed nephritic range proteinuria. The laboratory profile was within normal limits for perinuclear-anti-neutrophil cytoplasmic antibody, cytoplasmic-anti-neutrophil cytoplasmic antibody, anti-saccharomyces cerevisiae antibody, antinuclear antibody test, celiac profile, lactate, carbohydrate antigen-125 and thyroid stimulating hormone. A colonoscopy was completed, which revealed diffuse colonic lymphoid reactive hyperplasia. A small bowel series was negative for any inflammation. An indium scan, pan-computed tomography scan and transvaginal ultrasound were also negative. Magnetic resonance angiography of her abdomen revealed proximal superior mesenteric artery stenosis, which was confirmed by computed tomography angiogram findings of severe proximal and distal superior mesenteric artery stenosis, consistent with the appearance of fibromuscular dysplasia on angiography in the absence of vasculitis or atherosclerotic disease. The patient's superior mesenteric artery stenosis was subsequently angioplastied suboptimally and had to be stented with an Angioplus stent. One month after she was admitted, her abdominal pain and tolerance to oral feeds improved tremendously.</p> <p>Conclusion</p> <p>Fibromuscular dysplasia most commonly presents with renal artery stenosis, which rarely causes abdominal pain. This case illustrates how fibromuscular dysplasia can present as a rare cause of chronic mesenteric ischemia, similar to chronic mesenteric ischemia from atherosclerosis.</p